ATE331528T1 - Präparationen, die virus-ähnliche partikel als immunpotentiatoren enthalten und durch die schleimhaut verabreicht werden. - Google Patents

Präparationen, die virus-ähnliche partikel als immunpotentiatoren enthalten und durch die schleimhaut verabreicht werden.

Info

Publication number
ATE331528T1
ATE331528T1 AT99957844T AT99957844T ATE331528T1 AT E331528 T1 ATE331528 T1 AT E331528T1 AT 99957844 T AT99957844 T AT 99957844T AT 99957844 T AT99957844 T AT 99957844T AT E331528 T1 ATE331528 T1 AT E331528T1
Authority
AT
Austria
Prior art keywords
mucosa
administered
particles
preparations containing
containing virus
Prior art date
Application number
AT99957844T
Other languages
English (en)
Inventor
Rubido Julio Cesar Aguilar
Gardon Daniel Octav Palenzuela
Gonzalez Verena Lucila Muzio
Nieto Gerardo Enrique Guillen
Arias Eduardo Penton
Diaz Dagmara Pichardo
Perez Enrique Iglesias
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Application granted granted Critical
Publication of ATE331528T1 publication Critical patent/ATE331528T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99957844T 1998-12-02 1999-12-01 Präparationen, die virus-ähnliche partikel als immunpotentiatoren enthalten und durch die schleimhaut verabreicht werden. ATE331528T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1998183A CU22871A1 (es) 1998-12-02 1998-12-02 Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal

Publications (1)

Publication Number Publication Date
ATE331528T1 true ATE331528T1 (de) 2006-07-15

Family

ID=5459504

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99957844T ATE331528T1 (de) 1998-12-02 1999-12-01 Präparationen, die virus-ähnliche partikel als immunpotentiatoren enthalten und durch die schleimhaut verabreicht werden.

Country Status (13)

Country Link
US (1) US7374766B1 (de)
EP (1) EP1136077B1 (de)
CN (1) CN1191853C (de)
AR (1) AR021414A1 (de)
AT (1) ATE331528T1 (de)
BR (1) BR9915946B1 (de)
CA (1) CA2352777C (de)
CU (1) CU22871A1 (de)
DE (1) DE69932182T2 (de)
ES (1) ES2264273T3 (de)
HK (1) HK1042424B (de)
PT (1) PT1136077E (de)
WO (1) WO2000032229A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0031079D0 (en) * 2000-12-20 2001-01-31 Smithkline Beecham Plc Vaccine
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
AU2003277448A1 (en) 2002-10-17 2004-05-04 Enzo Therapeutics, Inc. Transmucosal administration of aggregated antigens
CU23405A1 (es) * 2003-10-20 2009-08-04 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas para uso terapéutico
EP1764369A1 (de) 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
EP3344293A4 (de) 2015-09-04 2019-01-16 Inventprise, LLC. Vlp-stabilisierte impfstoffzusammensetzungen
US10159728B2 (en) 2015-09-10 2018-12-25 Inventprise, Llc Multivalent VLP conjugates
EA201892212A1 (ru) 2016-03-31 2019-03-29 Сентро Де Инхеньерия Хенетика И Биотекнолохия Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b
TWI634899B (zh) * 2016-11-22 2018-09-11 國立臺灣大學 包含類ｂ肝病毒顆粒作為佐劑的疫苗組成物
MX2020013240A (es) * 2018-06-05 2021-05-12 Toko Yakuhin Kogyo Kk Sistema de administracion transnasal de la vacuna contra la hepatitis b.
US11389519B2 (en) 2018-06-11 2022-07-19 Inventprise, Llc Virus-like particle conjugates
EP4034158A4 (de) * 2019-09-23 2023-10-04 Ascendo Biotechnology, Inc. Biologisch abbaubare nanokomplex-impfstoffe, verfahren zur unterdrückung der hepapitis-b-virus-replikation und der hepapitis-b-virus-oberflächenantigensekretion
CN111450245A (zh) * 2020-04-29 2020-07-28 艾棣维欣(苏州)生物制药有限公司 一种乙型肝炎治疗疫苗及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547368A (en) * 1983-12-20 1985-10-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hepatitis B core antigen vaccine made by recombinant DNA
US4882145A (en) 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US6319501B1 (en) * 1990-07-19 2001-11-20 Health Research, Inc. Method of immunizing against hepatitis B virus
US5840303A (en) 1991-08-26 1998-11-24 The Scripps Research Foundation Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
JP3738395B2 (ja) * 1991-08-26 2006-01-25 エピミューン，インコーポレイティド Ｈｌａ−制限型ｂ型肝炎ウィルスのｃｔｌエピトープ
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
DE69319728T2 (de) 1992-05-23 1999-02-04 Smithkline Beecham Biologicals S.A., Rixensart Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
AU5679394A (en) 1992-11-25 1994-06-22 International Biotechnology Laboratories, Inc. Hepatitis b virus vaccines
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
FR2732605B1 (fr) 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
RU2189254C2 (ru) * 1995-06-06 2002-09-20 Америкэн Хоум Продактс Корпорэйшн Вакцины против вирусов гепатита
US6153392A (en) 1997-07-30 2000-11-28 Bionova Corporation Devices and methods comprising an HBcAg from hepatitis B virus
CA2302545C (en) 1997-09-05 2012-04-03 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties

Also Published As

Publication number Publication date
WO2000032229A1 (es) 2000-06-08
PT1136077E (pt) 2006-10-31
BR9915946A (pt) 2001-08-21
DE69932182D1 (de) 2006-08-10
CN1332637A (zh) 2002-01-23
CN1191853C (zh) 2005-03-09
CA2352777A1 (en) 2000-06-08
ES2264273T3 (es) 2006-12-16
BR9915946B1 (pt) 2010-12-14
AR021414A1 (es) 2002-07-17
EP1136077A1 (de) 2001-09-26
CU22871A1 (es) 2003-10-21
US7374766B1 (en) 2008-05-20
DE69932182T2 (de) 2007-05-10
EP1136077B1 (de) 2006-06-28
HK1042424B (en) 2007-05-11
CA2352777C (en) 2009-09-08
HK1042424A1 (en) 2002-08-16

Similar Documents

Publication Publication Date Title
ZA200407868B (en) 17alpha-Alkyl-17beta-oxy-estratrienes, uses thereof and pharmaceutical preparations.
EE200200151A (et) Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend
DE60117859D1 (de) HARNSTOFFSUBSTITUIERTE IMIDAZOCHINOLINETHER und Arzneimittel, die diese umfassen.
DE69932182D1 (de) Präparationen, die virus-ähnliche partikel als immunpotentiatoren enthalten und durch die schleimhaut verabreicht werden.
DZ2887A1 (fr) Dérivés d'azétidine, leur préparation et les médicaments les contenant.
WO2003024396A3 (en) Dry powder medicament formulations
ZA200007299B (en) Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol.
WO2002036771A3 (en) Imaging, diagnosis and treatment of disease
WO2001034137A3 (en) Oncolytic combinations for the treatment of cancer
ZA200208761B (en) Pharmaceutical form of administration for peptides, methods for its production and use.
HUP0302193A3 (en) 1,4-diazabicyclo[3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation thereof and pharmaceutical compositions containing them
EP1762620A3 (de) Antigene aus Cryptosporidium parvum, Antikörper dagegen und diagnostische und therapeutische Zusammensetzungen
WO2000003724A1 (en) Preparations for immunotherapy for cancer having bacterial somatic constituent as the active ingredient
EP1558282A4 (de) Zusammensetzungen gegen krebs und infektionskrankheiten und anwendungsverfahren dafür
FR2721023B1 (fr) Nouveaux Taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
WO2001034198A3 (en) Oncolytic combinations for the treatment of cancer
BG106517A (en) Ciclesonide-containing aqueous pharmaceutical composition
WO2000055194A3 (en) Tuberculosis antigens and methods of use therefor
AU2001230571A1 (en) Ultrafine mixed-crystal oxide particles, process for producing the same, and use
CA2455208A1 (en) Method of encapsulating an active substance
Chomsky Comments: Galen Strawson, Mental Reality
WO1999012945A3 (en) Hydrophobic glycosylamine derivatives, compositions, and methods for use
WO2001034134A3 (en) Oncolytic combinations for the treatment of cancer
JPH116484A5 (de)
RU96115480A (ru) Лекарственное средство, обладающее холелитолитическим действием

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1136077

Country of ref document: EP

REN Ceased due to non-payment of the annual fee